Strategies in treating newly diagnosed or untreated multiple myeloma patients. from the Multiple Myeloma Research Foundation
Weber, D.M.
Oncology 17(6): 765-767
2003
ISSN/ISBN: 0890-9091 PMID: 12846120 Document Number: 556323
Treatment regimens for multiple myeloma are evolving because of new advances in both pharmacotherapy and transplantation strategies. The Multiple Myeloma Research Foundation (MMRF) has gathered the top thought leaders in myeloma research to prepare an engaging, interactive series of case studies in multiple myeloma, which are available online at www.multiplemyeloma.org and will be published on a regular basis in ONCOLOGY.
Document emailed within 1 workday
Related Documents
Li, J.; Zhao, Y.; Luo, S.-K.; Huang, B.-H.; Zhang, G.-C.; Peng, A.-H.; Zheng, D.; Su, C.; Xu, D.-R.; Tong, X.-Z.; Gu, J.-L.; Ding, Y. 2008: The clinical features, chemotherapy responses and survival of 223 patients with newly diagnosed multiple myeloma Zhonghua Yi Xue Za Zhi 88(30): 2140-2143Zahran, A.M.; Sayed, M.M.; Shafik, E.A.; Khallaf, S.M.; Mohamed, W.M.; Hetta, H.F. 2019: The Frequency and clinical Implications of Lymphocyte Subsets and Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Patients Egyptian Journal of Immunology 26(2): 117-131
Stadtmauer, E.A. 2010: Tailoring initial treatment for newly diagnosed, transplantation-eligible multiple myeloma Oncology 24(3 Suppl 2: 7-13
Ohashi, K. 2008: Clinical implications of bortezomib in frontline treatment of newly-diagnosed multiple myeloma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(6): 1029-1032
Dingli, D.; Rajkumar, S.Vincent.; Nowakowski, G.S.; Gertz, M.A.; Dispenzieri, A.; Lacy, M.Q.; Hayman, S.; Fonseca, R.; Lust, J.A.; Kyle, R.A.; Greipp, P.R.; Witzig, T.E. 2005: Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial Haematologica 90(12): 1650-1654
Teunissen, L.L.; Notermans, N.C. 1998: The risk of Kahler disease (multiple myeloma) in patients with a paraproteinemia: myeloma risk score, developed in the region of the Integral Cancer Center, West Nederlands Tijdschrift Voor Geneeskunde 142(43): 2374-2375
Miwa, A. 2007: Advances in therapeutic strategies for multiple myeloma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(13): 2200-2216
Pasqualetti, P.; Casale, R.; Collacciani, A.; Colantonio, D. 1989: Evaluation of a morphologic staging method (myeloma progression score) in multiple myeloma Medicina 9(3): 280-282
Barlogie, B.; Alexanian, R. 1989: Second International Workshop on Myeloma: advances in biology and therapy of multiple myeloma Cancer Research 49(24 Pt 1): 7172-7175
Wu, M-Jei.; Fang, H-Chang.; Chang, T-Yuan.; Lo, Y-Shing.; Chung, H-Min. 2002: Multiple myeloma with myeloma nephropathy in a patient with Hashimoto's thyroiditis Journal of the Formosan Medical Association 101(6): 421-424
Borden, E.C. 1994: Innovative treatment strategies for non-Hodgkin's lymphoma and multiple myeloma Seminars in Oncology 21(6 Suppl 14: 14-22
García Laraña, J.; Díaz Mediavilla, J.; Martínez, R.; Lahuerta, J.J.; Alegre, A.; Odriozola, J.; Sureda, A.; San Miguel, J.; De la Rubia, J.; Escudero, A.; Conde, E.; Bladé, J.; Cabrera, R.; Gastearena, J.; Besalduch, J.; Vidal, M.J.; Hernández, F.; Rifon, J.; Leon, A.; Mataix, R.; Parody, R.; Moraleda, J.M.; Solano, C.; de Pablos, J.M.; Sánchez, J.J. 1997: Maintenance treatment with interferon-alfa in multiple myeloma after autotransplantation of peripheral blood progenitor cells. Spanish Register of Transplantation in Myeloma Sangre 42(Suppl 1): 38-41
Khoddami, M.; Esphehani, F.N.; Aslani, F.S. 1992: Ascites as a presenting feature of relapsed multiple myeloma. Report of a case diagnosed by aspiration cytology Acta Cytologica 36(3): 325-328
Showalter, K.; Maize, J.; Altomare, I.; Fisher, G. 2013: Multiple myeloma diagnosed secondary to analysis of a lytic bone lesion encountered during Mohs micrographic surgery Dermatology Online Journal 19(8): 19262
Takahashi, T.; Makiguchi, Y.; Hinoda, Y.; Kakiuchi, H.; Nakagawa, N.; Imai, K.; Yachi, A. 1994: Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient Journal of Immunology 153(5): 2102-2109
Rajkumar, S.V. 2008: Controversies regarding the use of dexamethasone in patients with multiple myeloma Clinical Advances in Hematology and Oncology: H&o 6(2): 103; 141
Lund, T.; Gregersen, H.; Vangsted, A.; Marker, P.; Abildgaard, N. 2009: Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma Ugeskrift for Laeger 171(1-2): 50-52
Katagiri, S.; Yonezawa, T.; Tsubakio, T.; Tamaki, T.; Kanakura, Y.; Kanayama, Y.; Kuyama, J.; Hiraoka, A.; Tarui, S. 1984: T cell subsets in patients with multiple myeloma Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 47(6): 1351-1358
Pick, A.I.; Schonfeld, J.; Schreibman, S.; Frohlichman, R.; Pinkhas, J. 1974: Multiple myeloma. a study of forty patients Israel Journal of Medical Sciences 10(11): 1371-1378
Basit, A.; Siddiqui, N.; Hameed, A.; Muzaffar, N.; Athar, S. 2014: Factors affecting outcome of patients with multiple myeloma Journal of Ayub Medical College Abbottabad: Jamc 26(3): 376-379